Phase 2 N=57 RAD001 Plus Bevacizumab in Metastatic Melanoma
Metastatic Melanoma
Primary: Progression-free Survival — 4 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 The Effect of Neurontin on Pain Management in the Acutely Burned Patient
Pain · Burn Injury
Primary: Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents) — 7.0; 6.7 morphine equivalents — p=<0.05
Phase 3 N=27 Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
Inflammation · Burns · Ulcers
Primary: Wound Are at Baseline
Phase 2 N=128 Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
Multiple Sclerosis
Primary: Percentage of Participants With Antibody Titer ≥40 at 28 Days Post Vaccination — 97.5; 97.4; 97.7; 90.0 percentage of participants
Phase 3 N=571 S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival at 2 Years — 76; 80 percentage of participants — p=0.11
Phase 4 N=81 Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
Glaucoma, Open-Angle
Primary: Change From Baseline in Average Intraocular Pressure (IOP) — 28.4; 28.5; -13.5; -11.4 Millimeters of Mercury (mmHg)
Phase 2 N=25 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Number of Patients With Response as Defined by IWG (International Working Group) Criteria for Myelodysplasia — 7; 4; 0; 9 participants
Phase 4 N=1,902 Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III
Heart Disease
Primary: For the Primary Endpoint the Reduction of Ventricular Therapies (ATP and Shocks) Delivered for Treating Fast Spontaneous Arrhythmia Episodes Was Measured. — 67.1; 41.9…
Phase 1 N=46 Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0; 0; 1 participants
N/A N=46 Effects of Levetiracetam (Keppra) on Alcohol Consumption
Alcohol Abuse · Drug Abuse
Primary: Standard Alcoholic Drinks Per Treatment Period — 41.2; 45.4 number of drinks per treatment period
Phase 2 N=16 Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple Myeloma
Primary: Number of Confirmed Responses, Defined to be an sCR, CR, VGPR, or PR Noted as the Objective Status on Two Consecutive Evaluations. — 0; 0; 0; 0 participants
Phase 2 N=44 Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change in LDL-C After 8 Weeks of Therapy — -39.6; -49.9 Percent Change
N/A N=8 Bosentan and Pulmonary Endothelial Function
Pulmonary Arterial Hypertension
Primary: Acetylcholine Vascular Reactivity Response — 180 percentage of baseline
Phase 4 N=331 Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
Depression
Primary: Inventory of Depressive Symptomatology-Clinician Administered (IDS-C) Mean Change From Baseline to Week 22 of the Acute Phase (ITT Population). — -9.96; -10.29; -10.30…
N/A N=64 A Pilot Clinical Trial of Varenicline as a Treatment for Alcohol Dependence
Substance Dependence
Primary: Average Number of Cigarettes Smoked Between the Varenicline and Placebo Groups for Completers Through Week 12. — 788.94; 403.24 cigarettes